[go: up one dir, main page]

NO20084915L - Nikotinacetylcholinreseptorligander 101 - Google Patents

Nikotinacetylcholinreseptorligander 101

Info

Publication number
NO20084915L
NO20084915L NO20084915A NO20084915A NO20084915L NO 20084915 L NO20084915 L NO 20084915L NO 20084915 A NO20084915 A NO 20084915A NO 20084915 A NO20084915 A NO 20084915A NO 20084915 L NO20084915 L NO 20084915L
Authority
NO
Norway
Prior art keywords
acetylcholine receptor
receptor ligand
nicotine acetylcholine
methods
nicotine
Prior art date
Application number
NO20084915A
Other languages
English (en)
Inventor
Timothy Martin Piser
Hui-Fang Chang
Eifion Phillips
James Woods
Thomas Simpson
Rebecca Urbanek
Christopher Holmquist
Hui Xiong
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084915(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084915L publication Critical patent/NO20084915L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Nikotin acetylkolin reseptor ligander av formel I, hvor X, n, R' og R 2 er som beskrevet i redegjørelsen, diasteromerer, enantiomerer, farmasøytisk akseptable salter, fremgangsmåter for tillaging, farmasøytiske sammensetninger inneholdende, og fremgangsmåter for å benytte det samme.
NO20084915A 2006-05-17 2008-11-21 Nikotinacetylcholinreseptorligander 101 NO20084915L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74747606P 2006-05-17 2006-05-17
US82497506P 2006-09-08 2006-09-08
PCT/SE2007/000485 WO2007133155A1 (en) 2006-05-17 2007-05-16 Nicotinic acetylcholine receptor ligands 101

Publications (1)

Publication Number Publication Date
NO20084915L true NO20084915L (no) 2009-02-13

Family

ID=38694158

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084915A NO20084915L (no) 2006-05-17 2008-11-21 Nikotinacetylcholinreseptorligander 101

Country Status (19)

Country Link
US (2) US7842803B2 (no)
EP (1) EP2019831B1 (no)
JP (1) JP2009537517A (no)
KR (1) KR20090007753A (no)
AR (1) AR060914A1 (no)
AU (1) AU2007250560B2 (no)
BR (1) BRPI0711941A2 (no)
CA (1) CA2652610A1 (no)
CL (1) CL2007001405A1 (no)
EC (1) ECSP088971A (no)
ES (1) ES2392997T3 (no)
IL (1) IL195019A0 (no)
MX (1) MX2008014436A (no)
NO (1) NO20084915L (no)
RU (1) RU2441007C2 (no)
SA (1) SA07280244B1 (no)
TW (1) TW200813067A (no)
UY (1) UY30349A1 (no)
WO (1) WO2007133155A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2009066107A1 (en) * 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
MX2013008704A (es) 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
CA3083244C (en) 2011-10-20 2023-01-03 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
JP6114951B2 (ja) 2012-12-11 2017-04-19 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アクチベーターによる処置に対する応答性を予測するバイオマーカー
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
ES2883232T3 (es) 2013-01-15 2021-12-07 Novartis Ag Uso de agonistas del receptor nicotínico de acetilcolina alfa 7
WO2017156309A1 (en) * 2016-03-09 2017-09-14 Msato, Llc Pellet shaped marking round for air rifles and pistols
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
EP1397366B1 (en) * 2001-06-01 2007-02-07 AstraZeneca AB Novel ligand for nicotinic acetylcholine receptors useful in therapy
MXPA04010191A (es) * 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos de furilo.
BR0309345A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa
ES2348282T3 (es) * 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
BRPI0414633A (pt) * 2003-09-25 2006-11-07 Astrazeneca Ab composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit

Also Published As

Publication number Publication date
KR20090007753A (ko) 2009-01-20
CL2007001405A1 (es) 2008-01-25
ES2392997T3 (es) 2012-12-17
CA2652610A1 (en) 2007-11-22
US7842803B2 (en) 2010-11-30
BRPI0711941A2 (pt) 2011-12-13
TW200813067A (en) 2008-03-16
AU2007250560B2 (en) 2011-06-23
JP2009537517A (ja) 2009-10-29
IL195019A0 (en) 2009-08-03
US20110136804A1 (en) 2011-06-09
AR060914A1 (es) 2008-07-23
EP2019831B1 (en) 2012-09-12
MX2008014436A (es) 2008-11-27
EP2019831A1 (en) 2009-02-04
AU2007250560A1 (en) 2007-11-22
SA07280244B1 (ar) 2011-06-22
WO2007133155A1 (en) 2007-11-22
ECSP088971A (es) 2009-01-30
RU2441007C2 (ru) 2012-01-27
US20080139600A1 (en) 2008-06-12
RU2008143450A (ru) 2010-06-27
EP2019831A4 (en) 2010-06-09
UY30349A1 (es) 2008-01-02

Similar Documents

Publication Publication Date Title
NO20084915L (no) Nikotinacetylcholinreseptorligander 101
NO20073551L (no) Nikotinacetylkolinreseptorligander
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2008006795A3 (en) Indole compounds
TW200643013A (en) Pyrazoles
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
NO20073547L (no) Nikotinacetykolinreseptorligander
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
NO20081862L (no) Alkylsulfoksidkinoliner som NK-3-reseptorligander
IL181666A0 (en) Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof
WO2009081246A3 (en) Bicyclic diamines as nicotinic receptor agonists
WO2008019971A3 (en) Arylpiperazine derivatives and uses thereof
TW200626567A (en) Benzoxazine and quinoxaline derivatives and uses
SE0400285D0 (sv) Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application